DANBIO: a nationwide registry of biological therapies in Denmark.
Since the year 2000, Danish rheumatologists have been collecting data on a routine basis in the nationwide DANBIO registry, which includes all rheumatologic patients receiving biological drugs. Demographic data, markers of disease activity, current treatment, serious and non-serious adverse events and reasons for discontinuation are registered at each visit either on paper forms or on-line. By June 2005, approximately 3000 treatment courses (18,000 visits) were in the registry, corresponding to close to 90% of eligible patients. Rheumatoid arthritis was the most prevalent diagnosis (75%) followed by ankylosing spondylitis (11%) and psoriatic arthritis (7%). Infections occurred in 43% of the treatment series.
Hetland
M L
ML
DANBIO, Copenhagen University Hospital at Hvidovre, Department of Rheumatology, Hvidovre, Denmark. merete.hetland@dadlnet.dk
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D016208:Databases, Factual; D003718:Denmark; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D011379:Prognosis; D012042:Registries; D012216:Rheumatic Diseases / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D012219:Rheumatology / Q000379:methods*; D012720:Severity of Illness Index
D018501:Antirheumatic Agents; D001688:Biological Products